Literature DB >> 171663

Comparison between growth characteristics of an Epstein--Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro.

M Steinitz, G Klein.   

Abstract

The GC-BJAB cell line, which carries the Epstein--Barr virus (EBV), was derived from an EBV-genome-negative lymphoma line (BJAB) by EBV infection in vitro [G. B. Clements, G. Klein, and S. Povey (1975) Int. J. Cancer, in press]. Both lines grow at a similar rate at 37 degrees but they differ at other temperatures. BJAB grows well at 34 degrees, 37 degrees, and 39 degrees. GC-BJAB grows at 37 degrees and 39 degrees, but grows poorly at 34 degrees. At 37 degrees, GC-BJAB cultures can be maintained at the viable state for a long time after having reached saturation density (approximately 10(6) cells per ml). In contrast, BJAB cultures die very soon after having attained similar maximum density. Since the identity of the two cell lines has been critically established [Clements et al.; E. Svedmyr and M. Jondal (1975) Proc. Nat. Acad. Sci USA 72, 1622--1626; G. Klein, to be published; J. Zeuthen, personal communication] the remarkable differences in their growth properties must be attributed to the EBV genome.

Entities:  

Mesh:

Year:  1975        PMID: 171663      PMCID: PMC433026          DOI: 10.1073/pnas.72.9.3518

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  9 in total

1.  Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis.

Authors:  E Svedmyr; M Jondal
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

Review 2.  Classification and biological nature of established human hematopoietic cell lines.

Authors:  K Nilsson; J Pontén
Journal:  Int J Cancer       Date:  1975-02-15       Impact factor: 7.396

3.  The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV.

Authors:  K Nilsson; G Klein; W Henle; G Henle
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

4.  Infection of EBV-genome-negative and -positive human lymphoblastoid cell lines with biologically different preparations of EBV.

Authors:  G Klein; B Sugden; W Leibold; J Menezes
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

5.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

6.  Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies.

Authors:  T Lindahl; G Klein; B M Reedman; B Johansson; S Singh
Journal:  Int J Cancer       Date:  1974-06-15       Impact factor: 7.396

7.  A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

8.  High-frequency establishment of human immunoglobulin-producing lymphoblastoid lines from normal and malignant lymphoid tissue and peripheral blood.

Authors:  K Nilsson
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

9.  Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.

Authors:  G Klein; T Lindahl; M Jondal; W Leibold; J Menézes; K Nilsson; C Sundström
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

  9 in total
  18 in total

1.  Optimal transactivation by Epstein-Barr nuclear antigen 1 requires the UR1 and ATH1 domains.

Authors:  Gyanendra Singh; Siddhesh Aras; Arnold H Zea; Shahriar Koochekpour; Ashok Aiyar
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

2.  EBNA-1, a bifunctional transcriptional activator.

Authors:  Gregory Kennedy; Bill Sugden
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

3.  Integrated viral DNA sequences in Epstein-Barr virus-converted human lymphoma lines.

Authors:  M Andersson-Anvret; T Lindahl
Journal:  J Virol       Date:  1978-03       Impact factor: 5.103

4.  Initiation points for cellular deoxyribonucleic acid replication in human lymphoid cells converted by Epstein-Barr virus.

Authors:  A Oppenheim; Z Shlomai; H Ben-Bassat
Journal:  Mol Cell Biol       Date:  1981-08       Impact factor: 4.272

5.  Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21).

Authors:  J D Fingeroth; M L Clabby; J D Strominger
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

6.  In vitro selection of RNA ligands for the ribosomal L22 protein associated with Epstein-Barr virus-expressed RNA by using randomized and cDNA-derived RNA libraries.

Authors:  M Dobbelstein; T Shenk
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

7.  Appearance of cytoskeletal components on the surface of leukemia cells and of lymphocytes transformed by mitogens and Epstein-Barr virus.

Authors:  R J Bachvaroff; F Miller; F T Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

Review 8.  Epstein-Barr virus (EBV), lymphocytes and transformation.

Authors:  J Zeuthen
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

9.  Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line.

Authors:  J Lacy; W P Summers; M Watson; P M Glazer; W C Summers
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

10.  Induction of B cell responsiveness to growth factors by Epstein-Barr virus conversion: comparison of endogenous factors and interleukin-1.

Authors:  B A Blazar; A M Murphy
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.